|
WO2021064629A1
|
|
Separation of neutral oligosaccharides from fermentation broth
|
|
US2020354761A1
|
|
Oligosaccharide production
|
|
WO2020255054A1
|
|
Nucleic acid construct comprising 5' utr stem-loop for in vitro and in vivo gene expression
|
|
WO2020250185A1
|
|
Human milk oligosaccharides and compositions thereof for use in preventing, managing or treating symptoms related to migraine
|
|
WO2020245757A1
|
|
Human milk oligosaccharides for use in the treatment of symptoms in a patient suffering from non-coeliac wheat and/or gluten sensitivity
|
|
WO2020178774A1
|
|
Human milk oligosaccharides for use in enhancing executive function
|
|
WO2020148693A1
|
|
Amorphous sialylated oligosaccharides
|
|
WO2020128945A1
|
|
Separation of oligosaccharides
|
|
WO2020128948A1
|
|
Composition and method for promoting intestinal barrier healing
|
|
WO2020128947A1
|
|
Composition and method for treating humans using low-fodmap diets
|
|
US2020138838A1
|
|
Composition comprising hmss/hmos and use thereof
|
|
WO2020115671A1
|
|
Synthesis of the fucosylated oligosaccharide lnfp-v
|
|
BR112020022892A2
|
|
mixture of hmos for treatment of autoimmune diseases
|
|
WO2019123316A1
|
|
Composition comprising hmos for preventing or reducing nociception
|
|
CN111727253A
|
|
Nucleic acid constructs for in vitro and in vivo gene expression
|
|
CN111683665A
|
|
Human milk oligosaccharides for microbiota regulation and synthetic compositions thereof
|
|
CN111556755A
|
|
Human milk oligosaccharides for the treatment of migraine
|
|
CN111698994A
|
|
HMO mixtures for treating wheat sensitivity
|
|
EP3456836A1
|
|
Separation of sialylated oligosaccharides from fermentation broth
|
|
EP3672600A1
|
|
Synthetic composition for reducing allergy symptoms
|
